Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 StudiesJohn N. Allan, Jon Arnason, Hesham Mohamed et al.|Blood|2024Cited by 6